Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Fulgent Genetics, |
RCV002485565 | SCV002785188 | uncertain significance | Charlevoix-Saguenay spastic ataxia | 2022-03-30 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002532174 | SCV003691739 | uncertain significance | Inborn genetic diseases | 2021-12-20 | criteria provided, single submitter | clinical testing | The c.11942A>G (p.Q3981R) alteration is located in exon 10 (coding exon 9) of the SACS gene. This alteration results from a A to G substitution at nucleotide position 11942, causing the glutamine (Q) at amino acid position 3981 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Mayo Clinic Laboratories, |
RCV000676349 | SCV000802123 | uncertain significance | not provided | 2017-06-14 | no assertion criteria provided | clinical testing |